Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth M Steinberg

Showing results (151-160 of 481) with videos related to

Pageof 49
Sort By:
Molecular and Cellular Biology|April 10, 2002
RAG-mediated V(D)J recombination is not essential for tumorigenesis in Atm-deficient miceLisa K Petiniot, Zoë Weaver, Melanie Vacchio, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 21, 2007
Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counselingJean Jenkins, Kathleen A Calzone, Eileen Dimond, et al.
Leukemia & Lymphoma|February 3, 2025
Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomasRahul Lakhotia, Christopher Melani, Kieron Dunleavy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV InfectionRamya Ramaswami, Mark N Polizzotto, Kathryn Lurain, et al.
Urologic Oncology|June 18, 2021
Clinical value of <sup>18</sup>FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancerAli Cahid Civelek, Scot A Niglio, Ashkan A Malayeri, et al.
The Journal of Laboratory and Clinical Medicine|March 2, 2002
Effects of interleukin 2 therapy on lymphocyte magnesium levelsMark D McKee, Stacey A Cecco, Julie E Niemela, et al.
Blood|February 5, 2010
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphomaKieron Dunleavy, Richard F Little, Stefania Pittaluga, et al.
Cytometry. Part B, Clinical Cytometry|April 24, 2008
Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemiaEjaz Ahmad, Seth M Steinberg, Lynn Goldin, et al.
Pediatric Blood & Cancer|October 6, 2007
Metabolic syndrome traits in long-term survivors of pediatric sarcomaKaren E Hoffman, Joanne Derdak, Donna Bernstein, et al.
Cancer Chemotherapy and Pharmacology|December 3, 2013
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumorsWoondong Jeong, Annamaria Rapisarda, Sook Ryun Park, et al.
Pageof 49

Showing results (151-160 of 481) with videos related to

Sort By:
Pageof 49
Molecular and Cellular Biology|April 10, 2002
RAG-mediated V(D)J recombination is not essential for tumorigenesis in Atm-deficient miceLisa K Petiniot, Zoë Weaver, Melanie Vacchio, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 21, 2007
Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counselingJean Jenkins, Kathleen A Calzone, Eileen Dimond, et al.
Leukemia & Lymphoma|February 3, 2025
Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomasRahul Lakhotia, Christopher Melani, Kieron Dunleavy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV InfectionRamya Ramaswami, Mark N Polizzotto, Kathryn Lurain, et al.
Urologic Oncology|June 18, 2021
Clinical value of <sup>18</sup>FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancerAli Cahid Civelek, Scot A Niglio, Ashkan A Malayeri, et al.
The Journal of Laboratory and Clinical Medicine|March 2, 2002
Effects of interleukin 2 therapy on lymphocyte magnesium levelsMark D McKee, Stacey A Cecco, Julie E Niemela, et al.
Blood|February 5, 2010
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphomaKieron Dunleavy, Richard F Little, Stefania Pittaluga, et al.
Cytometry. Part B, Clinical Cytometry|April 24, 2008
Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemiaEjaz Ahmad, Seth M Steinberg, Lynn Goldin, et al.
Pediatric Blood & Cancer|October 6, 2007
Metabolic syndrome traits in long-term survivors of pediatric sarcomaKaren E Hoffman, Joanne Derdak, Donna Bernstein, et al.
Cancer Chemotherapy and Pharmacology|December 3, 2013
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumorsWoondong Jeong, Annamaria Rapisarda, Sook Ryun Park, et al.
Pageof 49